MG
DMTK

Michael Gelband’s DermTech, Inc. Common Stock DMTK Stock Holding History

Michael Gelband’s Portfolio DMTK Stock Details DMTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,055
Closed -$61K – 2403
2022
Q2 		$61K Buy
+11,055
New +$90.5K ﹤0.01% 1783
2021
Q3 		– Sell
-12,458
Closed -$518K – 2777
2021
Q2 		$518K Buy
+12,458
New +$512K 0.01% 1371

Other funds holding DMTK

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Michael Gelband's DMTK Position: Q3 2022 in Review

Michael Gelband sold out of DermTech, Inc. Common Stock (DMTK) in Q3 2022, closing a stake of 11,055 shares — an estimated $61K sold.

Michael Gelband first reported a position in DMTK in Q2 2021 and held it in 2 quarters. The position peaked at $518K in Q2 2021. 127 funds tracked by Wall St. Rank hold DMTK as of Q3 2022.

  • Michael Gelband reported no remaining DermTech, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Michael Gelband sold 11,055 DermTech, Inc. Common Stock shares in Q3 2022, an estimated $61K.
  • Michael Gelband first reported a position in DermTech, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Michael Gelband's DermTech, Inc. Common Stock position peaked at $518K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held DermTech, Inc. Common Stock as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.